Ono Pharmaceutical (OTCMKTS:OPHLY – Get Free Report) is projected to release its results before the market opens on Wednesday, October 28th. Analysts expect Ono Pharmaceutical to post earnings of $0.0913 per share and revenue of $725.78 million for the quarter.
Ono Pharmaceutical Stock Performance
OTCMKTS:OPHLY opened at $5.26 on Wednesday. The company has a 50-day moving average of $5.03 and a 200-day moving average of $4.97. Ono Pharmaceutical has a twelve month low of $3.82 and a twelve month high of $5.75.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd. is a Japan-based, research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its activities focus primarily on areas of high unmet medical need, including oncology, immunology, neurology and other specialty-care fields.
The company’s best-known product is Opdivo (nivolumab), an immune checkpoint inhibitor used in the treatment of multiple cancers. Ono has also developed or commercialized other specialty medicines, including treatments for cancer and immune-related conditions, through internal research and collaborations with pharmaceutical companies in Japan and overseas.
Ono Pharmaceutical traces its origins to 1717, when it began as a drug wholesaler in Osaka, and was incorporated in its modern corporate form in 1947.
Featured Stories
- Five stocks we like better than Ono Pharmaceutical
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
